SC rejects Novartis plea on Cancer drug patent

The Supreme Court on Monday rejected a plea by Swiss pharma giant Novartis AG for getting its blood cancer drug Glivec patented in India. The Bench dismissed the plea that primarily focuses on demands by major companies that their investments be protected, against Indian companies demanding they should be allowed to continue producing cheaper indigenous generic versions of many lifesaving medicines. The patents would be granted only for genuine inventions, cited the Supreme Court, a decision that paves way for Indian companies to manufacture generic drugs for cancer.